139 related articles for article (PubMed ID: 1891900)
21. Serum lipoprotein pattern after SAMe-treatment.
Rini GB; Di Fede G; Rotolo G; Rizzo G; Mascellino MR; Affronti M; Delle Vedove G
Boll Soc Ital Biol Sper; 1987 Oct; 63(10):919-22. PubMed ID: 3447603
[No Abstract] [Full Text] [Related]
22. Changes induced by gemfibrozil on lipidic, coagulative and fibrinolytic pattern in patients with type IV hyperlipoproteinemia.
Avellone G; Di Garbo V; Panno AV; Cordova R; Lepore R; Strano A
Int Angiol; 1988; 7(3):270-7. PubMed ID: 3198979
[TBL] [Abstract][Full Text] [Related]
23. [Plafibride treatment of hyperlipidemias type II and IV].
Soler J; Vinzia C; Gómez JM; Morató J
Med Clin (Barc); 1984 May; 82(19):840-2. PubMed ID: 6738212
[No Abstract] [Full Text] [Related]
24. [Multicenter study of the efficacy and tolerance of gemfibrozil and fenofibrate in the treatment of primary hyperlipoproteinemia].
Manojlović D; Lepsanović L; Micić D; Sumarac M; Kendereski L; Popović V; Mićić J
Srp Arh Celok Lek; 1991; 119(1-2):22-5. PubMed ID: 1788614
[TBL] [Abstract][Full Text] [Related]
25. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
Noseda G; Fragiacomo C; Weidmann P; Bachmann C
Schweiz Med Wochenschr; 1980 Dec; 110(49):1875-7. PubMed ID: 7455660
[TBL] [Abstract][Full Text] [Related]
26. Gemfibrozil--a new lipid lowering agent.
Nash DT
J Med; 1980; 11(2-3):107-16. PubMed ID: 6931871
[TBL] [Abstract][Full Text] [Related]
27. Pirifibrate in the treatment of hyperlipoproteinemia: types IIa, IIb, and IV.
Lopez Rodriguez J; Martorell J
Clin Ther; 1980; 3(4):234-41. PubMed ID: 7273061
[TBL] [Abstract][Full Text] [Related]
28. [Comparison of the hypolipemic effects of bezafibrate and fenofibrate in patients with hyperlipoproteinemia type II and IV].
Sznajderman M
Przegl Lek; 1984; 41(7):493-9. PubMed ID: 6390536
[No Abstract] [Full Text] [Related]
29. Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
Hutt V; Wechsler JG; Klör HU; Ditschuneit H
Artery; 1980; 8(2):113-9. PubMed ID: 7458676
[TBL] [Abstract][Full Text] [Related]
30. [Clinical research on the hypolipidemic action of a probucol preparation].
Naumova R; Kerekovska M; Goranov I; Balabanski L
Vutr Boles; 1986; 25(2):73-7. PubMed ID: 3716382
[TBL] [Abstract][Full Text] [Related]
31. Fenofibrate for the treatment of type IV and V hyperlipoproteinemias: a double-blind, placebo-controlled multicenter US study.
Goldberg AC; Schonfeld G; Feldman EB; Ginsberg HN; Hunninghake DB; Insull W; Knopp RH; Kwiterovich PO; Mellies MJ; Pickering J
Clin Ther; 1989; 11(1):69-83. PubMed ID: 2655907
[TBL] [Abstract][Full Text] [Related]
32. Effects of slow-release bezafibrate on serum lipids, lipoproteins, apolipoproteins, and postheparin lipolytic activities in patients with type IV and type V hypertriglyceridemia.
Saku K; Sasaki J; Arakawa K
Clin Ther; 1989; 11(3):331-40. PubMed ID: 2743372
[TBL] [Abstract][Full Text] [Related]
33. [Long-term effects of a glycosaminoglycan on plasma lipids].
Avogaro P; Bittolo-Bon G; Alessandrini P
Clin Ter; 1981 Jul; 98(1):47-61. PubMed ID: 7249572
[No Abstract] [Full Text] [Related]
34. [Combined therapy of hyperlipoproteinemia. Colestipol and gemfibrozil in the treatment of heterozygous familial hypercholesterolemia].
Ceska R; Sobra J; Toschnerová H; Traurig J
Cas Lek Cesk; 1992 Mar; 131(6):183-5. PubMed ID: 1586935
[TBL] [Abstract][Full Text] [Related]
35. [Hyperlipoproteinemia, HDL-cholesterol and arteriosclerosis indices].
Herrmann W; Reuter W
Z Gesamte Inn Med; 1982 Dec; 37(24):830-3. PubMed ID: 6963524
[No Abstract] [Full Text] [Related]
36. [Correction of dyslipoproteinemia in middle-aged and elderly patients with atherosclerosis using Essentiale in combination with adebit].
Korkushko OV; Bogatskaia LN; Kovalenko AN; Novikova SN; Kotko DN
Vrach Delo; 1989 Aug; (8):19-22. PubMed ID: 2588515
[TBL] [Abstract][Full Text] [Related]
37. Effects of gemfibrozil on plasma lipoprotein-apolipoprotein distribution and platelet reactivity in patients with hypertriglyceridemia.
Sirtori CR; Franceschini G; Gianfranceschi G; Sirtori M; Montanari G; Tremoli E; Maderna P; Colli S; Zoppi F
J Lab Clin Med; 1987 Sep; 110(3):279-86. PubMed ID: 3475394
[TBL] [Abstract][Full Text] [Related]
38. Long-term treatment of hyperlipoproteinemia with etofibrate: clinical observations.
Kaffarnik H; Schneider J; Schubotz R; Zöfel P; Hausmann L; Goebel KM
Artery; 1980; 8(6):537-46. PubMed ID: 6114725
[TBL] [Abstract][Full Text] [Related]
39. Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III, and type IV hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemfibrozil.
Weintraub MS; Eisenberg S; Breslow JL
J Clin Invest; 1987 Apr; 79(4):1110-9. PubMed ID: 3470306
[TBL] [Abstract][Full Text] [Related]
40. [One year fenofibrate treatment of type II primary hyperlipidaemia. Effects on lipoproteins and biological tolerance (author's transl)].
Drouin P; Méjean L; Lambert D; Wülfert E; Debry G
Nouv Presse Med; 1980 Dec; 9(49):3753-7. PubMed ID: 7208342
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
